文献速递神经肿瘤

前瞻性连续基因组分析揭示脑膜瘤分子变异在不同人群中的分布

Prospective consecutive genomic profiling defines the distribution of meningioma molecular alterations across demographic groups.
PubMed 文献 · Neuro Oncol · 2026-08-19

该研究对2019至2025年在美国大型学术医疗中心连续治疗的1,044例脑膜瘤患者共1,104份肿瘤样本进行前瞻性二代DNA测序,分析拷贝数变异(CNA)和短体细胞变异(SSV)在不同人口学群体中的分布。结果显示亚洲男性脑膜瘤富集高风险分子特征,女性富集低风险分子特征,西班牙裔个体低级别脑膜瘤更常见。

要点

  • 亚洲男性脑膜瘤富集1p、6q、14q缺失、1q获得、1p/22q共缺失及CDKN2A/B纯合缺失等高风险特征。
  • 女性脑膜瘤富集TRAF7、AKT1、PIK3CA的短体细胞变异等低风险分子特征。
  • 西班牙裔与非西班牙裔白人脑膜瘤分子架构相似,但西班牙裔是低级别疾病的独立预测因素。

核心结论

  • 在美国连续前瞻性队列中,脑膜瘤CNA和SSV的分布因人口学群体而异。
  • 亚洲男性因富集既往未被认识的高风险分子特征,可能具有更高的临床侵袭性脑膜瘤风险。
  • 分子学预后良好的脑膜瘤在女性中更常见,低级别脑膜瘤在西班牙裔个体中更常见。

研究设计与样本

  • 前瞻性连续队列研究,纳入2019至2025年美国大型学术医疗中心1,044例连续脑膜瘤患者的1,104份肿瘤样本。
  • 对肿瘤样本进行前瞻性二代DNA测序,采用单因素和多因素回归分析人口学特征与CNA、SSV的关联。

主要发现

  • 亚洲男性脑膜瘤富集1p、6q、14q拷贝数缺失,1q拷贝数获得,1p/22q共缺失或1p缺失/1q获得共存,以及CDKN2A/B纯合缺失。
  • 女性脑膜瘤富集TRAF7、AKT1、PIK3CA的短体细胞变异。
  • 西班牙裔与非西班牙裔白人脑膜瘤的分子架构相似,但西班牙裔是低级别疾病的独立预测因素。

临床怎么用

  • 脑膜瘤分子分型应结合患者人口学特征(如性别、种族/族裔)进行解读。
  • 对亚洲男性脑膜瘤患者可关注高风险分子特征以辅助风险分层和治疗个体化。

局限性

  • 既往多数脑膜瘤生物学研究采用非连续、回顾性队列,存在患者和肿瘤选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular profiling is increasingly important for risk stratification and individualization of treatment recommendations for patients with meningioma. Prior investigations have established the genomic architecture of meningioma, but the distribution of meningioma copy number alterations (CNAs) and short somatic variants (SSVs) across demographic groups is incompletely understood. Here we define a prospective, consecutive benchmark for meningioma CNAs and SSVs across demographic groups. METHODS: Prospective next-generation DNA sequencing was performed on 1,104 tumor samples from 1,044 consecutive patients who were treated for meningioma or whose meningiomas underwent molecular testing at a large academic medical center in a major US city from 2019 to 2025. Univariate and multivariate regression analyses were performed to evaluate associations between demographic characteristics, CNAs, and SSVs. RESULTS: Meningiomas from Asian males were enriched in high-risk molecular features, including (1) copy number deletion of chromosomes 1p, 6q, and 14q, (2) copy number gain of chromosome 1q, (3) chromosome 1p/22q codeletion or co-occurrent 1p loss/1q gain, and (4) CDKN2A/B homozygous deletion. In contrast, meningiomas from females were enriched in low-risk molecular features, including SSVs in TRAF7, AKT1, and PIK3CA. The molecular architecture of meningiomas from Hispanic and non-Hispanic White individuals appeared similar, though Hispanic ethnicity was a unique independent predictor of low-grade disease. CONCLUSIONS: In this US-based cohort, the distribution of meningioma CNAs and SSVs varies across demographic groups. Asian males appear to have an increased risk of clinically aggressive meningioma due to enrichment in high-risk molecular features that were previously unappreciated in this patient population. Molecularly favorable meningiomas are more common in females, and low-grade meningiomas are more common in Hispanic individuals. Studying the biology of meningioma has improved understanding of the most common primary brain tumor and can be used to guide patient care. However, most investigations of meningioma biology have used non-consecutive, retrospective cohorts of patients. Such cohorts are susceptible to biases in terms of which patients and which tumors are available for investigation. Thus, examination of meningioma biology across different groups of patients based on age, sex, or race/ethnicity has been limited. This study reports biological data from meningiomas across groups of patients based on age, sex, and race/ethnicity in a large, US-based, consecutive, prospective cohort. The data presented here establish a benchmark for the molecular architecture of meningioma across demographic groups.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Braman BC, Nguyen MP, Mirchia K, et al. Prospective consecutive genomic profiling defines the distribution of meningioma molecular alterations across demographic groups. Neuro Oncol. 2026. PMID: 42616658. doi:10.1093/neuonc/noag196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。